March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
January 2026 in “Mendeley Data” January 2026 in “Mendeley Data” 
January 2026 in “Dermatology Practical & Conceptual” This retrospective cohort study analyzed 142 patients with nonscarring alopecia treated with low-dose oral minoxidil (LDOM) to assess the association between patient demographics and adverse effects (AEs). The study found that AEs were relatively uncommon, with only 13.3% of patients experiencing any AE, and no significant association was found between AEs and demographics such as sex, age, race, or ethnicity. The findings suggest that LDOM is a safe treatment for hair loss, with AEs being less common than previously thought, and that patient demographics do not impact the risk of AEs. The study highlights the importance of individualized monitoring for AEs, considering other factors like patient weight. Limitations include the small cohort size and retrospective design.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
April 2025 in “Pakistan Journal of Health Sciences” Weekly Azathioprine Pulse therapy is more effective than Betamethasone Oral Mini-Pulse for hair regrowth in moderate to severe Alopecia Areata.
January 2025 in “AYUSHDHARA” Herbomineral drugs effectively manage chemotherapy-induced diarrhea in oral cavity cancer patients.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.